Help us: Donate
Follow us on:

Altering Macrophage Types to Treat Parkinson’s


As we reported in an article yesterday, researchers are becoming increasingly interested in the potential of changing the ratio of types of macrophages present in the body to facilitate tissue regeneration and healing.

This is a line of research that covers a number of topics, including aging, regeneration, tissue repair, and inflammation. Over the last year or so we have seen a number of publications focusing on altering populations of macrophages to elicit repair and regeneration of tissues, which is a positive sign that things are moving forward.

The balance between different types (known as polarizations) of macrophages is again the subject of another study, which we will discuss today[1]. This time the focus is on Parkinson’s disease and how changing the ratio of macrophage types could be a potential therapy for this devastating age-related disease.

Altering macrophage types

Macrophages are derived from monocytes, a type of immune cell which changes into one of a number of macrophage types, depending on local signalling when they arrive at the site of injury or damage.

As discussed in our previous article, the M1 and M2 types of macrophages are again in the spotlight and the potential of changing the ratio of M1 and M2 types is the focus.

M1-type macrophages tend to aggressively destroy problematic cells and cause inflammation when they do so, due to the inflammatory signals they secrete to recruit other immune cells to the site.

The problem is, when there are too many M1-type macrophages present, inflammation becomes excessive and this hinders the repair and regeneration of tissues.

The M2 type of macrophage can be considered a “healing” cell which favours and facilitates the suppression of inflammation as well as promoting tissue regeneration.

Falling costs may be encouraging progress

This increased interest in tweaking macrophage types is likely the result of the arrival of tools that allow for cost-effective approaches to change the ratio of macrophages. Progress in biotechnology is moving very rapidly, thanks in part to falling costs and refined techniques and equipment that make tasks far easier.

One only needs to consider CRISPR as an example of this: what was once a complex and time-consuming laborious process can now be rapidly achieved. The field is filled with similar examples,  and these breakthroughs in the tools researchers have at their disposal is fuelling a meteoric rise in research progress.

So onto the research

Researchers in this new study focus on a tissue resident type of macrophage known as microglia, which is present in the central nervous system. Changes to microglia are known to be important in the progression of a number of age-related neurodegenerative conditions, including Alzheimer’s, ALS, and Parkinson’s disease.

As we age, the immune system declines in the central nervous system, as it does in the rest of the body, causing it to become dysfunctional and generating excessive levels of inflammation driving the aging process even faster. This chronic inflammation, often referred to as “inflammaging”, hinders tissue maintenance and repair.

However, microglia have additional functions, such as helping to ensure the correct functioning of neurons and neural connections. In this paper, the researchers explore the idea of changing the ratio of microglia polarization to favour the healing M2 type as a potential way to address Parkinson’s disease.


It is great to see yet more researchers focusing on this area of research, and with the falling costs of the infrastructure of biotechnology, we are hopeful that interest will continue to grow in this area.

If you enjoyed this article and would like to support us to create more articles, events, livestream panels, talks and scientific advocacy, please consider becoming a Lifespan Hero.


[1] Subramaniam, S. R., & Federoff, H. J. (2017). Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson’s Disease. Frontiers in Aging Neuroscience, 9, 176.

About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 600 articles on the topic, interviewed over 100 of the leading researchers in the field, hosted livestream events focused on aging, as well as attending various medical industry conferences. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, Swiss Monthly, Keep me Prime, and New Economy Magazine. Steve is one of three recipients of the 2020 H+ Innovator Award and shares this honour with Mirko Ranieri – Google AR and Dinorah Delfin – Immortalists Magazine. The H+ Innovator Award looks into our community and acknowledges ideas and projects that encourage social change, achieve scientific accomplishments, technological advances, philosophical and intellectual visions, author unique narratives, build fascinating artistic ventures, and develop products that bridge gaps and help us to achieve transhumanist goals. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project.
No Comments
Write a comment:


Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Want the latest longevity news? Subscribe to our Newsletter!